Sub-Pharmacophore Generation of JNK3 Inhibitors

Abstract:

The structure-based pharmacophore (SBP) model is consisted by the complementarity of the chemical features and space of the interaction between the ligand and receptor. The SBP models always have a high specificity which can only represent the specific class of the ligand. To simplify the models, sub-pharmacophore was then proposed in present study, and was expected to have and only have the most important or the common chemical features which play the major role in the interaction of ligand and receptor. Sub-pharmacophore should contain 4-6 features, the higher specificity with more features, and vice versa. The sub-pharmacophore was generated by the random combination of features from the structure-based models. With the MDL Drug Data Report database used as the testing database, a new metric CAI (comprehensive appraisal index), which integrated the metrics of E and A%, was defined and used to determine the best sub-pharmacophore model. C-Jun N-terminal kinase (JNKs) is one of the mitogen-activated protein kinase family, and widely involved in immune response and inflammatory response, and other pathological processes. JNK3 is mainly distributed in the brain and nervous system. In present study, twenty-five initial SBP models of JNK3 inhibitors were directly constructed from the Protein Data Bank (PDB) complexes by the LigandScout software. Then, 1018 sub-pharmacophore models were obtained from the 25 initial models. Finally, the best sub-pharmacophore was determined which was simplified from the initial model generated from the 3FI2 complex, and included four features: one hydrogen bond donor, one hydrogen bond acceptor, and two hydrophobic groups. The metrics of E, A% and CAI value of the best sub-pharmacophore model are 17.47, 31.15 and 5.44, respectively. The potential JNK3 inhibitors were then identified from Chinese herbs with the best sub-pharmacophore model, and 286 compounds were obtained.

• Periodical: Applied Mechanics and Materials (Volumes 444-445)
• Pages: 1756-1760
• DOI: https://doi.org/10.4028/www.scientific.net/AMM.444-445.1756
• Online since: October 2013
• Authors: Yan Ling Zhang, Yuan Ming Wang, Yan Jiang Qiao
• Keywords: C-Jun N-Terminal Kinases 3, Comprehensive Appraisal Index, Structure-Based Pharmacophore, Sub-Pharmacophore

References

[1] T. Zhang, F. Inesta-Vaquera, M. Niepel, et al. Discovery of Potent and Selective Covalent Inhibitors of JNK, Chemistry & Biology, 2012, 19(1): 140–154.

DOI: 10.1016/j.chembiol.2011.11.010

[2] Z. Zhuang, Y. Wen, D. Zhang, et al., A Peptide c-Jun N-Terminal Kinase (JNK) Inhibitor Blocks Mechanical Allodynia after Spinal Nerve Ligation: Respective Roles of JNK Activation in Primary Sensory Neurons and Spinal Astrocytes for Neuropathic Pain Development and Maintenance, The Journal of Neuroscience, 2006, 26(13): 3551-3560.

DOI: 10.1523/jneurosci.5290-05.2006

[3] Z. Yao, K. Diener, X.S. Wang, et al. Activation of Stress-activated Protein Kinases/c-Jun N-terminal Protein Kinases (SAPKs/JNKs) by a Novel Mitogen-activated Protein Kinase Kinase (MKK7). The Journal of Biological Chemistry, 1997, 272(51): 32378-32383.

DOI: 10.1074/jbc.272.51.32378

[4] Accelrys Inc. Catalyst. Version 4. 10 Tutorials. San Diego: Accelrys Inc., (2005).

[5] F.G. Osman, Pharmacophore perception, development, and use in drug design, 1st ed., California: InternationalUniversity Line, 2000, p.197.

[6] L. Thierry, D.H. Remy, Pharmacophoresand pharmacophore searchs, volume 32, Wiley-VCH, 2006, pp.338-339.

[7] J.L. Stebbins, S.K. De, T. Machleidt, B. et al., Identification of a new JNK inhibitor targeting the JNK-JIP interaction site, PNAS, 2008, 105(43): 16809-16813.

DOI: 10.1073/pnas.0805677105